Jones Financial Companies
ZVRA icon

Jones Financial Companies’s Zevra Therapeutics ZVRA Stock Holding History

Jones Financial Companies’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.8K Buy
3,248
+640
+25% +$5.77K ﹤0.01% 3141
2025
Q4 		$23.4K Buy
2,608
+2,358
+943% +$22.3K ﹤0.01% 2867
2025
Q3 		$2.44K Buy
+250
New +$2.51K ﹤0.01% 3620

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Jones Financial Companies's ZVRA Position: Q1 2026 in Review

Jones Financial Companies increased its Zevra Therapeutics (ZVRA) stake by 25% in Q1 2026, buying an estimated $5.77K and bringing the position to 3,248 shares worth $29.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3141.

Jones Financial Companies first reported a position in ZVRA in Q3 2025 and has held it in 3 quarters since. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Jones Financial Companies held 3,248 shares of Zevra Therapeutics worth $29.8K as of Q1 2026.
  • Jones Financial Companies bought 640 Zevra Therapeutics shares in Q1 2026, an estimated $5.77K.
  • Zevra Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #3141 holding.
  • Jones Financial Companies first reported a position in Zevra Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.